Bearish Analyst Comments on Dendreon (DNDN)

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Analysts at Brean Capital are negative on pharmaceutical company Dendreon Corp. (NASDAQ: DNDN) and today maintained a Sell rating on the stock with a price target of $2. Overall, analysts said they simply can't see how Dendreon can break even and they also expect the EMA to reject prostate cancer drug Provenge.

"Revenues from academic accounts declined 9% QoQ. We attribute this decline to academics as physicians that perhaps think a little bit more about the attributes of a drug before using it, rather than thinking about a 6% profit, and thus with Provenge's arguably questionable path to approval, these physicians clearly disfavor it," said analyst Jonathan Aschoff.

Brean Capital has a Sell rating on Dendreon price target of $2.00.

For an analyst ratings summary and ratings history on Dendreon (NASDAQ: DNDN) click here. For more ratings news on Dendreon click here.

Shares of Dendreon closed at $5.67 yesterday, with a 52 week range of $3.69-$15.20.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
• Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
• UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?